Caladrius Biosciences (NASDAQ:CLBS) released its earnings results on Thursday. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05), Fidelity Earnings reports.
Shares of CLBS stock traded down $0.09 during mid-day trading on Friday, hitting $2.84. The stock had a trading volume of 17,401 shares, compared to its average volume of 30,320. Caladrius Biosciences has a fifty-two week low of $2.80 and a fifty-two week high of $11.65.
Several analysts have recently commented on CLBS shares. Zacks Investment Research cut shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. Dawson James restated a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, February 27th. HC Wainwright restated a “buy” rating and issued a $18.50 target price on shares of Caladrius Biosciences in a research note on Thursday, January 24th. Finally, ValuEngine cut shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $12.13.
ILLEGAL ACTIVITY WARNING: “Caladrius Biosciences (CLBS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.wkrb13.com/2019/05/11/caladrius-biosciences-clbs-posts-quarterly-earnings-results-misses-expectations-by-0-05-eps.html.
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.